The global HPAPIs market is expected to reach USD 34.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing number of new entrants producing fast relief therapeutics in emerging countries of India and China is anticipated to boost the demand for High potency active pharmaceutical ingredients (HPAPIs) over the forecast period.
In
addition, supportive government regulations for commercialization and research
and development of novel drug molecules are projected to drive the industry
growth. Extensive capital investments required for development of production
facility has lead to increase in contract manufacturing activities for HPAPIs
during the forecast period.
For Full Research Report On High Potency Active Pharmaceutical Ingredients Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/high-potency-active-pharmaceutical-ingredients-hpapi-market
Further Key
Findings From the Study Suggest:
- Synthetic route of High
PotencyAPIs dominated the overall market in terms of revenue share as of
2016 owing to presence of large manufacturers producing these type of
molecules
- Biotech HPAPI segment is
expected to be the fastest growing and is expected to grow at a lucrative
growth ratedue torising demand for cancer drugs and fueling research and
developmentactivities pertaining to it
- Innovative drug market
dominated the overall drug type in 2016. Generic drug segment is expected
to be the fastest growing segment. The factors attributing to its growth
are patent expiration of various drugs and increasing demand for the
cancer treatment
- Contact outsourcing segment
is anticipated to show lucrative growth as major pharmaceuticals are
focused on rigorous research and development activities for new drug
development
- Oncology segment heldlargest
revenue share as of 2016, due to increasing demand for anti-cancerous
drugs
- North America HPAPIs market
held the largest market share as of 2016. Growing prevalence of chronic
disease patients, and established research and development infrastructure
for novel drug development are factors supporting to major share of this
market
- Patent expiration of major
drugs in North American and European countries is anticipated to fuel
market growth
- Asia Pacific regional market
is expected to register significant growth owing to growing investments in
biotechnology sector and rapidly growing oncology market
- The key players in the HPAPI
market includeBristol-Myers Squibb, Sigma-Aldrich Corporation,
Pfizer Incand Lonza among others
- Extensive research and
development activities carried out by market participants is also expected
to augment the market growth
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/high-potency-active-pharmaceutical-ingredients-hpapi-market/request/rs1
Grand View Research has segmented
the High PotencyAPIsmarket on the basis of the product, manufactures, drug
types, application, and region:
HPAPIs Product
Outlook (Revenue, USD Million, 2014 - 2025)
- Synthetic
- Biotech
HPAPIs
Manufacturers Outlook (Revenue, USD Million, 2014 - 2025)
- In-house
- Outsourced
HPAPIs Drug Types
Outlook (Revenue, USD Million, 2014 - 2025)
- Innovative
- Generic
HPAPIs Application
Outlook (Revenue, USD Million, 2014 - 2025)
- Oncology
- Hormonal
- Glaucoma
- Others
HPAPIs Regional
Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment